StockData

Dianthus Therapeutics, Inc. (DNTH) bonds

DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$91.81−0.67 (-0.72%)

Close on Nov 13, 2026Market cap $5.14BP/E –Yield 0.00%

Debt

Borrowings on the balance sheet, Sep 30, 2026

Dianthus Therapeutics reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Notes and loans outstanding

As tagged in Dianthus Therapeutics's 10-K for the period ended Dec 31, 2018

IssueAmount issuedCarrying value
Convertible Promissory Notes
Convertible
$6.50M$7.20M

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-K.

See a number that looks wrong?